Kim S, Russell W, Price P, Saleem A
Department of Clinical Oncology, Christie Hospital, Manchester, UK.
Br J Radiol. 2008 Dec;81(972):963-9. doi: 10.1259/bjr/24432468. Epub 2008 Sep 1.
We aimed to evaluate the use of intravenous (IV) contrast during acquisition of radiotherapy planning (RTP) scans and to compare current usage with the Royal College of Radiologists' (RCR) recommendations. Questionnaires were circulated via the Academic Clinical Oncology and Radiobiology Research Network (ACORRN) website, email and post to 60 UK radiotherapy centre managers. Questions were asked regarding the (i) tumour sites where IV contrast was used, (ii) person administering the contrast, (iii) availability of dynamic pump, (iv) tumour sites that centres wished to use contrast, (v) reasons for not using contrast and (vi) awareness of RCR recommendations. 50 (83%) centres responded to the questionnaire, of which 27 responded via the ACCORN website and 18 by e-mail. Despite 38 out of 50 responding centres using IV contrast, and accessibility to dynamic pumps existing in 39 centres, IV contrast usage was suboptimal, with more than half of the centres (27/50; 54%) wishing to use it at more tumour sites. IV contrast was most often used during RTP of the brain, with suboptimal usage in lung tumours. None of the 50 centres administered IV contrast during RTP scan acquisition in all of the 8 RCR recommended tumour sites. Radiographers were mainly responsible for contrast administration, and a lack of staff was cited as the main reason for suboptimal contrast usage. Disappointingly, only 35 of the 50 radiotherapy managers (70%) were aware of the RCR recommendations. Redress of the underlying reasons for suboptimal IV contrast administration during RTP, including acquisition of the necessary skill mix by staff and implementation of RCR recommendations, would help standardize UK practice.
我们旨在评估在获取放射治疗计划(RTP)扫描时静脉注射(IV)造影剂的使用情况,并将当前的使用情况与皇家放射科医师学院(RCR)的建议进行比较。通过学术临床肿瘤学和放射生物学研究网络(ACORRN)网站、电子邮件和邮寄的方式,向60位英国放射治疗中心经理发放了调查问卷。问题涉及(i)使用IV造影剂的肿瘤部位,(ii)给予造影剂的人员,(iii)动态泵的可用性,(iv)各中心希望使用造影剂的肿瘤部位,(v)不使用造影剂的原因,以及(vi)对RCR建议的知晓情况。50个(83%)中心回复了问卷,其中27个通过ACORN网站回复,18个通过电子邮件回复。尽管50个回复中心中有38个使用IV造影剂,且39个中心可以使用动态泵,但IV造影剂的使用并不理想,超过一半的中心(27/50;54%)希望在更多肿瘤部位使用它。IV造影剂最常用于脑部RTP,在肺部肿瘤中的使用不理想。在RCR推荐的所有8个肿瘤部位进行RTP扫描采集时,50个中心中没有一个在采集过程中给予IV造影剂。放射技师主要负责造影剂的给予,人员不足被认为是造影剂使用不理想的主要原因。令人失望的是,50位放射治疗经理中只有35位(70%)知晓RCR的建议。纠正RTP期间IV造影剂给予不理想的根本原因,包括让工作人员掌握必要的技能组合以及实施RCR的建议,将有助于规范英国的做法。